慢性乙型肝炎患者HBV DNA载量与血清miR-122、miR-223水平的关系

摘要/Abstract

摘要： 目的分析慢性乙型肝炎(CHB)患者乙型肝炎病毒脱氧核糖酸(HBV DNA)载量与血清微小RNA-122(miR-122)、微小RNA-223(miR-223)水平的关系。方法回顾性分析郑州市第七人民医院2022年6月—2023年3月收治的540例CHB患者的临床资料。依据血清HBV DNA载量分为低载量(＜10⁵拷贝/mL)组(n=230)、中载量(10⁵~10⁷拷贝/mL)组(n=180)、高载量(＞10⁷拷贝/mL)组(n=130),另选取同期于我院体检中心体检的健康者300名设为对照组。比较不同HBV DNA载量组血清miR-122、miR-223水平,绘制ROC曲线评价血清miR-122、miR-223诊断CHB的效能,采用多因素Logistic回归分析CHB的危险因素,采用Pearson相关性分析HBV DNA载量与血清miR-122、miR-223水平的关系。结果三组血清miR-122(1.45±0.37、2.84±0.72、4.11±0.90)、miR-223(1.34±0.33、1.69±0.37、1.91±0.45)比较差异有统计学意义(F=716.128、104.744, P<0.05);CHB组患者的血清miR-122(2.56±0.49)、miR-223(1.79±0.42)及HBV DNA载量＞10⁵拷贝/mL的人数占比(310/540)显著高于对照组(1.07±0.21、1.05±0.30、75/300)(t=51.844、26.935, χ²=81.585, P<0.05);经ROC分析证实,血清miR-122、miR-223水平均可用于预测CHB,曲线下面积分别为miR-122(AUC=0.794, 95%CI: 0.690~0.898)、miR-223(AUC=0.813, 95%CI: 0.720~0.906),均有P<0.05;多因素logistic回归分析显示,miR-122≥1.528、miR-223≥1.210及HBV DNA载量＞10⁵拷贝/mL是CHB的危险因素,OR值分别为2.011(95%CI: 1.211~3.339)、1.696(95%CI: 1.026~2.804)、2.117(95%CI: 1.974~3.987)均有P<0.05;相关性分析显示,血清miR-122、miR-223水平与HBV DNA载量呈正相关(r=0.753、0.712, P<0.05)。结论血清miR-122、miR-223水平与HBV DNA载量呈正相关,且miR-122≥1.528、miR-223≥1.210及HBV DNA载量＞10⁵拷贝/mL是CHB的危险因素,可将以上指标作为诊断CHB的生物学标志物,从而为临床病情评估和治疗提供参考。

关键词: 慢性乙型肝炎, 乙型肝炎病毒脱氧核糖酸载量, 微小RNA-122, 微小RNA-223, 乙型肝炎病毒

Abstract: Objective Exploring the correlation between hepatitis B virus deoxyribonic acid (HBV DNA) load and serum microRNA-122 (miR-122) and microRNA-223 (miR-223) levels in patients with chronic hepatitis B (CHB). Methods The clinical data of 540 patients with CHB who received treatment in our hospital from June 2022 to March 2023 were retrospectively analyzed. According to the serum HBV DNA load, the patients were divided into low load (＜10⁵ copies/mL) group (n=230), medium load (10⁵~10⁷ copies/mL) group (n=180) and high load (> 10⁷ copies/mL) group (n=130). Another selection of 300 healthy subjects was made during the same period in our hospital physical examination center to serve as control group. Serum miR-122 and miR-223 levels were compared in different HBV DNA load groups, ROC curve was drawn to evaluate the diagnostic efficacy of serum miR-122 and miR-223 in CHB, and the risk factors of CHB were analyzed by multivariate logistic regression. Pearson correlation analysis was used to investigate the correlation between HBV DNA load and serum levels of miR-122 and miR-223. Results Serum miR-122 (1.45±0.37, 2.84±0.72, 4.11±0.90) and miR-223 (1.34±0.33, 1.69±0.37, 1.91±0.45) were significantly different among the three groups (F=716.128, 104.744, P<0.05). The proportion of serum miR-122 (2.56±0.49), miR-223 (1.79±0.42) and HBV DNA load > 10⁵ copies/mL in CHB group (310/540) was significantly higher than that in control group (1.07±0.21, 1.05±0.30, 75/300) (t=51.844, 26.935, χ²=81.585, P<0.05); ROC analysis confirmed that serum miR-122 and miR-223 levels could be used to predict CHB, and the areas under the curve were miR-122 (AUC=0.794, 95%CI: 0.690~0.898) and miR-223 (AUC=0.813, 95%CI: 0.720~0.906), all P<0.05; Multivariate logistic regression analysis showed that miR-122 ≥ 1.528, miR-223 ≥ 1.210 and HBV DNA load > 10⁵ copies/mL were risk factors for CHB. OR values were 2.011 (95%CI: 1.211~3.339), 1.696 (95%CI: 1.026~2.804), 2.117 (95%CI: 1.974~3.987), and P<0.05, respectively. Correlation analysis showed that serum miR-122 and miR-223 levels were positively correlated with HBV DNA load (r=0.753, 0.712, P<0.05). Conclusion Serum miR-122 and miR-223 levels were positively correlated with HBV DNA load, and miR-122≥1.528, miR-223≥1.210 and HBV DNA load > 10⁵ copies/mL were risk factors for CHB. These indexes could be used as biological markers for the diagnosis of CHB so as to provide references for clinical condition evaluation and treatment.

Key words: Chronic hepatitis B, Hepatitis B virus deoxyribose acid load, MicroRNA-122, MicroRNA-223, Hepatitis B virus

杨丽, 孙君. 慢性乙型肝炎患者HBV DNA载量与血清miR-122、miR-223水平的关系[J]. 肝脏, 2024, 29(8): 947-951.

YANG Li, SUN Jun. Correlation between HBV DNA load and serum miR-122, miR-223 levels in patients with chronic hepatitis B[J]. Chinese Hepatolgy, 2024, 29(8): 947-951.

/ 推荐

参考文献 21

[1]	Hui M L, Fang F S, Yue X B, et al. Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection[J]. Hepatol Int,2023,17(1):42-51.
[2]	陆伟, 张占卿, 阎俪, 等. 血清定量HBsAg和HBV DNA预测HBeAg阳性慢性HBV感染显著肝炎活动的性能比较[J]. 肝脏,2023,28(1):86-94.
[3]	Eveline H, Bernard S, Blanco N B, et al. Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection[J].Clin Infect Dis,2023,76(4):730-733.
[4]	唐建华, 陈富强, 孙晓军, 等. 乙肝患者血清lncRNA NEAT1表达与HBV DNA载量,肝功及T淋巴细胞亚群的相关性[J]. 中国病原生物学杂志,2021,16(5):582-585,589.
[5]	桑珍珍, 高杰, 贾春梅, 等. 血清microRNA-122a、microRNA-124a及microRNA-125b对脓毒症休克并发肝损伤早期诊断及预后评估的临床价值[J]. 中国现代医学杂志,2020,30(2):27-33.
[6]	Eyileten C, Fitas A, Jarosz P J, et al. MicroRNA-223 might be a predictive biomarker for major adverse cardiovascular events prognosis in patients undergoing transcatheter aortic valve implantation procedur[J]e. Eur Heart J,2021,42(1):1-3.
[7]	中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 中华传染病杂志,2019,37(12):711-736.
[8]	祝方, 尹向东, 刘刚, 等. 深圳市罗湖乙肝综合防治示范区劳务工人乙肝病毒感染状况调查[J]. 中国公共卫生,2022,38(3):271-275.
[9]	付甜甜, 姚钊, 丁红, 等. 计算机辅助诊断慢性乙肝患者肝纤维化进程的价值分析[J]. 中华医学杂志,2019,99(7):491-495.
[10]	Richard K S, Wendy C K, Mandana K, et al. Performance of Serum-Based Scores for Identification of Mild Hepatic Steatosis in HBV Mono-infected and HBV-HIV Co-infected Adults[J]. Dig Dis Sci,2022,67(2):676-688.
[11]	潘正兰, 管世鹤, 陈礼文, 等. IL-6过表达慢病毒稳转细胞系构建及其对HBsAg、HBeAg、HBV DNA表达影响[J]. 安徽医科大学学报,2019,54(4):594-599,604.
[12]	王庆辉, 蒋瑞馨, 夏卫, 等. 隐匿性乙型肝炎病毒感染相关miRNAs筛选及其生物信息学分析[J]. 中国输血杂志,2020,33(3):217-222.
[13]	杜波, 高小丽, 白雪梅. 慢性乙型肝炎患者HBV DNA载量与血清microRNA-122,ALT的相关性研究[J]. 中国现代医学杂志,2020,30(24):86-90.
[14]	徐静, 张凤岐, 王聪, 等. 血清miR-223, HMGB1与乙肝患者HBV DNA载量和肝功能的关系研究[J]. 国际病毒学杂志,2021,28(4):332-335.
[15]	Sarah A E R, Sloan D J, Wilna O, et al. MicroRNA-122 and cytokeratin-18 have potential as a biomarkers of drug-induced liver injury in European and African patients on treatment for mycobacterial infection[J]. Br J Clin Pharmacol,2021,87(8):3206-3217.
[16]	袁冲, 赵征, 廖子君, 等. 血清miR-122和miR-570联合检测对原发性肝癌的临床诊断价值[J]. 现代肿瘤医学,2021,29(2):267-270.
[17]	罗艳香, 程含, 吴波, 等. 慢性HBV感染血清miR-122和miR-155与miR-375表达及意义[J]. 中华医院感染学杂志,2021,31(21):3230-3234.
[18]	龚晓媛, 万舒淇, 傅承宏. 乙型病毒肝炎及晚期肝纤维化患者血清中miR-223的表达及临床意义[J]. 中国病原生物学杂志,2021,16(10):1202-1206.
[19]	李丽敏, 秦雪. miR-223在原发性肝癌患者血清中的表达及临床意义. 广西医科大学学报[J],2019,36(5):808-811.
[20]	Shareef S, Ebrahimi S O. Contribution of hsa-miR-146a and hsa-miR-223 gene variations in patients with multiple sclerosis reveals association of rs2910164 and rs1044165 with risk of multiple sclerosis susceptibility[J]. J Investig Med,2021,69(5):1015-1021.
[21]	Heba E A, Nadia E G, Enas M R, et al. Possible Use of miR-223-3p as a Prognostic Marker in Transarterial Chemoembolization Treatment of Hepatocellular Carcinoma Patients[J]. Asian Pac J Cancer Prev,2022,23(12):4125-4135.